Patents Assigned to Monarch Medical Technologies, LLC
-
Publication number: 20210085870Abstract: In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.Type: ApplicationFiled: November 20, 2020Publication date: March 25, 2021Applicant: MONARCH MEDICAL TECHNOLOGIES, LLCInventors: TIMOTHY L. RUCHTI, WILLIAM PATRICK BURGESS, JOHN DUMAS, III, RONALD LISIECKI, CAROL DIAN MARTIN, LAURA SANTANA, JOHN HARRISON THORNLEY, JOANNE MARIE WATT
-
Patent number: 10842935Abstract: In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.Type: GrantFiled: July 30, 2018Date of Patent: November 24, 2020Assignee: Monarch Medical Technologies, LLCInventors: Timothy L. Ruchti, William Patrick Burgess, John Dumas, III, Ronald Lisiecki, Carol Dian Martin, Laura Santana, John Harrison Thornley, Joanne Marie Watt
-
Publication number: 20180333535Abstract: In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.Type: ApplicationFiled: July 30, 2018Publication date: November 22, 2018Applicant: Monarch Medical Technologies, LLCInventors: Timothy L. Ruchti, William Patrick Burgess, John Dumas, III, Ronald Lisiecki, Carol Dian Martin, Laura Santana, John Harrison Thornley, Joanne Marie Watt
-
Patent number: 10046113Abstract: In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.Type: GrantFiled: December 21, 2012Date of Patent: August 14, 2018Assignee: Monarch Medical Technologies, LLCInventors: Timothy L. Ruchti, William Patrick Burgess, John Dumas, III, Ronald Lisiecki, Carol Dian Martin, Laura Santana, John Harrison Thornley, Joanne Marie Watt